The list of the "2022 Chinese Biopharma Companies Innovation TOP 100 Series Lists" was released on June 28, 2023 at the annual conference of the MENET. While reviewing and summarizing China's pharmaceutical innovation in 2022, the conference predicted and looked forward to the future. For the third consecutive year, Genor Biopharma won the title of "Chinese Antibody Drug Companies Innovation TOP 30".
In 2023, policies to promote economic growth were introduced one after another. The enthusiasm for new drug research and development is also higher, and enterprises have promoted innovation and urgently need to create good results. Based on the "Enterprise Innovation Ability Evaluation Index System" of the Ministry of Science and Technology as the theoretical basis, MENET summarized the innovation ability evaluation index into four dimensions of "innovation input", "innovation achievement", "intellectual property" and "innovation-driven", and 11 index systems. Combined with the annual report of innovative drug enterprises, CDE review data, third-party patent statistical institutions and public data statistics, the innovative drug enterprises were comprehensively evaluated.
In 2022, Genor Biopharma continued to focus on the potential global first-in-class (FIC)/best-in-class (BIC) innovation pipeline, the company has developed and is executing a comprehensive strategy to optimize and enrich the existing product portfolio and conduct molecular research with the greatest potential to produce clinical and commercially viable drugs. It aims to address unmet medical needs in China and around the world.
Cooperative R&D and open innovation, Genor Biopharma is actively exploring cooperation projects between its platform for early discovery of highly differential T-cell Engager / bi-specific/multi-specific antibodies in immune-oncology / BsADC and different innovative technology platforms to further promote global innovation through cooperation. In May 2022, Genor Biopharma entered into a cooperative development agreement with Abogen Biosciences Co., Ltd. (“Abogen”) to jointly develop globally innovative mRNA products and related pharmaceuticals. GH Biopharma’s antibody development platform will be integrated with Abogen’s mRNA technology platform to enable them to jointly research and develop mRNA drugs for tumor treatment. It is progressing smoothly. One of the collaborative projects is in the pre-pcc stage. Currently, the Group is exploring opportunities to conduct cooperative development projects with various innovative technology platforms. It is actively expanding external cooperation in early research and development, commercialization and other levels, in order to continuously expand global innovation.
Over the past year, the efficacy of GB261 (CD20/CD3, BsAb) has been observed in the first-in-human (FIH) clinical trial in Australia in the dose-climbing low-dose group with preliminary clinical Proof of Concept (POC) data. Current clinical data suggest that GB261 has the potential to become a globally differentiated CD20/CD3 drug. The first human (FIH) clinical trial in Australia and the Phase I/II clinical trial in China of GB263T (EGFR/cMET/cMET, TsAb) are progressing rapidly. Clinical Proof of Concept (POC) data is expected in 2023.
NMPA has officially accepted the new drug application for GB491 (Lerociclib) in combination with Fluvestran as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy.
The LEONARDA-1 data has been posted during ASCO’s Metastatic Breast Cancer session with the abstract title as: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy, and has been recognized at global. Based on the efficacy and safety data presented in the LEONARDA-1, Lerociclib (GB491) is expected to be a more reliable clinical option for patients with HR+/HER2- advanced breast cancer. Lerociclib (GB491) could become a preferred option among CDK4/6 inhibitors for patients with suboptimal recovery of myelosuppression after chemotherapy and suboptimal gastrointestinal / hepatic function or patients with poor tolerability.
“Chinese Biopharma Companies Innovation TOP 100 Series Lists” was initiated by MENET, aiming to guide China's biomedical enterprises to be innovation-driven and innovation-results-oriented, strengthen innovation investment and intellectual property capabilities, and promote the improvement of the innovation level of Chinese biomedical enterprises and industry from the perspective of innovation index ranking. The list has attracted the attention and praise of pharmaceutical industry.
